hailir(SH:603639)2025-04-28 16:10Financial Performance - The company's operating revenue for 2024 was CNY 3,907,553,145.61, a decrease of 11.16% compared to CNY 4,398,440,072.42 in 2023[23]. - The net profit attributable to shareholders for 2024 was CNY 181,372,732.58, down 61.67% from CNY 473,202,442.19 in 2023[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 163,198,596.07, a decline of 66.87% compared to CNY 492,632,801.10 in 2023[23]. - Cash flow from operating activities for 2024 was CNY 285,551,955.88, a significant drop of 70.11% from CNY 955,352,084.08 in 2023[23]. - Basic earnings per share for 2024 were 0.53 RMB, a decline of 61.87% from 1.39 RMB in 2023[24]. - The weighted average return on equity for 2024 was 5.30%, down from 14.49% in 2023, representing a decrease of 9.19 percentage points[24]. Audit and Compliance - The financial report has been audited by Zhongxinghua Accounting Firm, which issued a standard unqualified opinion[5]. - The board of directors and supervisory board members confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has committed to ensuring the financial report's authenticity and accuracy through its responsible personnel[5]. - The internal control audit was conducted by Zhongxinghua Accounting Firm, resulting in a standard unqualified opinion report[199]. - The company has effectively implemented internal controls over its subsidiaries, with no significant deficiencies reported[198]. Risk Management - The company reported no significant risks affecting its production and operations during the reporting period[10]. - The company has outlined various risks and countermeasures in the management discussion section of the report[10]. - The company has not violated decision-making procedures for external guarantees[8]. - There were no non-operating fund occupations by controlling shareholders or related parties[8]. Market and Product Development - The company is actively expanding its international market presence and enhancing cooperation with multinational companies[31]. - New product developments include the trial production of several pesticide active ingredients, with projects entering trial production in 2024[32]. - The company has introduced several new pesticide products, including the insecticides Thiamethoxam and Acetamiprid, which are expected to enhance market competitiveness and drive revenue growth[38]. - The company’s main active ingredient products include insecticides and fungicides, with a focus on diversifying and enriching its pesticide offerings[38]. - The market for biopesticides, such as Abamectin, is expected to grow significantly, reflecting a broader trend towards environmentally friendly agricultural practices[43]. Strategic Initiatives - The company is focusing on cost reduction and efficiency improvement to enhance market competitiveness[31]. - The company plans to continue its dual-driven strategy of integrating active ingredients and formulations while expanding both domestic and international markets[64]. - The company is committed to reducing the use of chemical pesticides, targeting a coverage rate of 45% for integrated pest management in major grain crops by 2025[131]. - The company aims to achieve sales growth and cost control by 2025, while accelerating qualification construction in pesticide registration and GLP testing[143]. Governance and Management - The governance structure is continuously improved to ensure compliance with laws and protect shareholder rights, with independent oversight from the board and supervisory committee[155]. - The company maintains independence from its controlling shareholders, ensuring no interference in its operations and adherence to legal obligations[156]. - The company emphasizes transparency in information disclosure, ensuring all shareholders have equal access to relevant information[158]. - The company has established a talent training program focusing on new employees and ongoing professional development for existing staff[182]. Shareholder Returns - The profit distribution plan for 2024 proposes a cash dividend of 5 RMB per 10 shares (including tax), subject to shareholder approval[6]. - The company plans to distribute a cash dividend of 5 RMB (including tax) for every 10 shares, with a total cash dividend amounting to 169,949,168 RMB, which represents 93.7% of the net profit attributable to ordinary shareholders in the consolidated financial statements[187][191]. - Over the last three accounting years, the cumulative cash dividend amount (including tax) reached 680,182,662 RMB, with an average annual net profit of 371,528,355.75 RMB, resulting in a cash dividend ratio of 183.08%[192]. Research and Development - The company has synthesized over 6,888 new compounds and achieved three lead compounds during the reporting period[102]. - The company has submitted 104 invention patent applications and achieved 58 new patent certifications during the reporting period[102]. - The company is committed to increasing R&D investment to develop high-efficiency, low-toxicity, and environmentally friendly pesticide formulations to achieve product differentiation[149]. Financial Management - The company has approved a comprehensive credit limit application for 2024, including corresponding guarantee limits[161]. - The company has approved the use of idle funds for purchasing financial products, enhancing financial management strategies[174]. - The total remuneration for directors and senior management during the reporting period amounted to 7.03 million yuan[163].